When a health program reaches a similar endpoint, what burden has been shifted to patients and caregivers?
A main clinical or program endpoint can look similar while treatment duration, visits, cost, transport, trust, and access change substantially.
Program-level recovery and household-level burden moved differently in recent nutrition research, making single-endpoint judgments incomplete.
- Who encounters this friction
- Implementation researchers, nutrition-program teams, health systems, patients, and caregivers.
In one severe acute malnutrition study, fixed dosing produced a similar recovery proportion but longer treatment and greater caregiver costs. Separate interviews identified transport, poverty, education, trust, and discrimination as parts of the care setting.
An intervention can appear efficient at the program level while transferring time or cost to families. Those effects influence whether benefits persist outside a study.
Joint measurement of clinical outcomes, relapse, time, household cost, access, and implementation fidelity in the same populations and across different settings.
What changed
Newest evidence first. Labels describe the bottleneck, not treatment effectiveness.
-
Mixed
A dosing comparison and a separate caregiver study showed why recovery, duration, cost, access, and lived context require distinct measurements.
2 linked primary sources
Primary studies and briefings
2 primary sources. Every interpretation remains bounded by the linked evidence.
Nutrition
Read the DiseaseSignal evidence briefing
- Fixed and standard RUTF dosing study PMID 42306972 · DOI 10.1111/mcn.70201
- Koraga mothers' child-nutrition perceptions study PMID 42335139 · DOI 10.1371/journal.pone.0351319
How to read evidence movement
EmergingA newly supported problem worth tracking.
StrengtheningAdditional evidence reinforces the bottleneck framing.
MixedEvidence supports some parts while important conflicts or limits remain.
UnchangedNew evidence does not materially change the open problem.
WeakenedNew evidence reduces confidence that this is the central bottleneck.
These labels track an unresolved research problem. They do not score a treatment or predict benefit for an individual.